For the most part, analysts maintained their long-term bullish stance on Nvidia.
Thursday’s big stock stories: What’s likely to move the market in the next trading session
The S&P 500 booked back-to-back gains Wednesday as tech giants — including Nvidia — jumped during the session.
Options trading activity is flashing a warning sign about the market
Traders are buying up protective puts or selling covered calls against the S&P 500, says Scott Nations of Nations Indexes. Volatility is likely on the way.
How you can squeeze a little more yield from your idle cash in exchange for a bit of risk
Not all money market funds are built the same. Some funds offer investors a bump in interest income if they’re willing to take a little more risk.
A key financial ETF is now so depressed that it may be ready to bounce vs. the broad market
IAI’s selloff in 2026 has led to underperformance vs. the S&P 500, leaving the IAI/SPX relative ratio oversold, a rare occurrence over the past few years.
Nvidia earnings are out after market close. Here’s what Wall Street expects to see
Analysts remain bullish on Nvidia given strong AI capex expected this year, healthy AI compute demand and the stock’s valuation relative to hyperscaler peers.
Anthropic goes from software foe to friend. These stocks should benefit
Anthropic positioned its products as additive, rather than threatening, to existing software providers, analysts said.
Are collectibles a viable asset class? The buyer of the $16.5 million Pokémon card thinks so
AJ Scaramucci thinks trading cards have experienced tremendous growth, and thus they, and other collectibles, are great alternative investments.
Analysts see a turnaround for this unique e-commerce play after a unit sale and strong earnings
This is “one of the top five most visited websites, more than a lot of household names,” one analyst said.
Direct-to-consumer sales for obesity drugs are about to boom. JPMorgan sees Eli Lilly as big winner
Thanks to its “best-in-class” status, the bank believes the company will be the winner from a growing GLP-1 patient base.